A medicine comprising a combination of erythropoietin and granulocyte colony stimulating factor, and a method for using erythropoietin and granulocyte colony stimulating factor in the production
A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then administering to the subject an effective combined amount of EPO and G-CSF. Also disclosed is a method for increasing in a subject expression of EPO with G-CSF.